Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 1
2008 2
2009 3
2010 3
2011 2
2012 1
2013 2
2014 3
2015 3
2016 4
2017 2
2018 2
2019 2
2020 1
2021 5
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions.
Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. Werner GS, et al. Among authors: gelev v. Eur Heart J. 2018 Jul 7;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220. Eur Heart J. 2018. PMID: 29722796 Clinical Trial.
Technical tips for a successful transradial procedure.
Doganov A, Gelev V, Krastev V. Doganov A, et al. Among authors: gelev v. Indian Heart J. 2008 Jan-Feb;60(1 Suppl A):A9-A13. Indian Heart J. 2008. PMID: 19359757 Review. No abstract available.
Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO).
Werner GS, Hildick-Smith D, Martin Yuste V, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, Di Mario C, Teruel L, Bufe A, Lauer B, Galassi AR, Louvard Y. Werner GS, et al. Among authors: gelev v. EuroIntervention. 2023 Sep 18;19(7):571-579. doi: 10.4244/EIJ-D-23-00312. EuroIntervention. 2023. PMID: 37482940 Free article. Clinical Trial.
Local Deuteration Enables NMR Observation of Methyl Groups in Proteins from Eukaryotic and Cell-Free Expression Systems.
Dubey A, Stoyanov N, Viennet T, Chhabra S, Elter S, Borggräfe J, Viegas A, Nowak RP, Burdzhiev N, Petrov O, Fischer ES, Etzkorn M, Gelev V, Arthanari H. Dubey A, et al. Among authors: gelev v. Angew Chem Int Ed Engl. 2021 Jun 14;60(25):13783-13787. doi: 10.1002/anie.202016070. Epub 2021 May 6. Angew Chem Int Ed Engl. 2021. PMID: 33768661 Free PMC article.
A new paradigm for transcription factor TFIIB functionality.
Gelev V, Zabolotny JM, Lange M, Hiromura M, Yoo SW, Orlando JS, Kushnir A, Horikoshi N, Paquet E, Bachvarov D, Schaffer PA, Usheva A. Gelev V, et al. Sci Rep. 2014 Jan 20;4:3664. doi: 10.1038/srep03664. Sci Rep. 2014. PMID: 24441171 Free PMC article.
Aromatic 19F-13C TROSY: a background-free approach to probe biomolecular structure, function, and dynamics.
Boeszoermenyi A, Chhabra S, Dubey A, Radeva DL, Burdzhiev NT, Chanev CD, Petrov OI, Gelev VM, Zhang M, Anklin C, Kovacs H, Wagner G, Kuprov I, Takeuchi K, Arthanari H. Boeszoermenyi A, et al. Among authors: gelev vm. Nat Methods. 2019 Apr;16(4):333-340. doi: 10.1038/s41592-019-0334-x. Epub 2019 Mar 11. Nat Methods. 2019. PMID: 30858598 Free PMC article.
Author Correction: The cardiac molecular setting of metabolic syndrome in pigs reveals disease susceptibility and suggests mechanisms that exacerbate COVID-19 outcomes in patients.
Ziegler O, Sriram N, Gelev V, Radeva D, Todorov K, Feng J, Sellke FW, Robson SC, Hiromura M, Alexandrov BS, Usheva A. Ziegler O, et al. Among authors: gelev v. Sci Rep. 2021 Oct 28;11(1):21613. doi: 10.1038/s41598-021-00995-z. Sci Rep. 2021. PMID: 34711865 Free PMC article. No abstract available.
Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction.
Nishikawa JL, Boeszoermenyi A, Vale-Silva LA, Torelli R, Posteraro B, Sohn YJ, Ji F, Gelev V, Sanglard D, Sanguinetti M, Sadreyev RI, Mukherjee G, Bhyravabhotla J, Buhrlage SJ, Gray NS, Wagner G, Näär AM, Arthanari H. Nishikawa JL, et al. Among authors: gelev v. Nature. 2016 Feb 25;530(7591):485-9. doi: 10.1038/nature16963. Epub 2016 Feb 17. Nature. 2016. PMID: 26886795 Free PMC article.
42 results